Cloud PR Wire

Author: Kathir J

  • EKOUAER Wins Multiple Prestigious International Media Awards, Showcasing Brand Excellence

    International lifestyle brand EKOUAER has garnered a series of heavyweight accolades and recommendations from global authoritative media outlets in 2024, thanks to its innovative designs and exceptional quality. These honors not only solidify its leadership in the fashion and lifestyle sectors but also highlight widespread recognition from consumers and industry experts alike.

    Featured in Shop TODAY 2024 “AS SEEN ON” Annual List

    Multiple EKOUAER products were selected for Shop TODAY 2024’s “AS SEEN ON” Annual Picks, a highly influential list curated by NBC’s TODAY show, spotlighting Amazon’s best-selling and top-rated items of the year. EKOUAER’s standout offerings, celebrated for their unique designs, premium comfort, and affordability, have become hot favorites for holiday gifting.

    CNN Underscored “Editor’s Pick 2024”

    EKOUAER’s  Winter Loungewear Collection earned a coveted spot in CNN Underscored’s “Editor’s Favorite Winter Pajamas”* list. The editorial team praised its “ultra-soft, skin-friendly fabrics, chic minimalist tailoring, and thoughtful details that balance practicality with aesthetics,” dubbing it “the ultimate cozy companion for chilly seasons.”

    Forbes “Best Beach Cover-Ups” Recognition

    EKOUAER’s Beach Cover-Up Series was named one of the “Best Beach Cover-Ups”* in *Forbes’ annual roundup, hailed as a must-have for style-savvy travelers. Editors applauded its “lightweight, breathable fabric, versatile elegance, and seamless fusion of sun protection with runway-ready flair,”noting that it *“redefines standards for resortwear.”

    About EKOUAER  

    Founded in 2015, EKOUAER is a global fashion brand committed to delivering high-quality, comfort-focused sleepwear and loungewear. Leveraging proprietary fabric technologies for unparalleled softness, the brand has rapidly expanded its reach, serving millions of customers across 180+ countries. EKOUAER remains dedicated to enhancing everyday comfort, prioritizing designs that blend luxury, functionality, and timeless style to elevate the sleep and leisure experience.

  • China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum

    SHENZHEN, CHINA – On March 17, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. Profit for the year was RMB1,613 million, and normalized profit for the year that excluding the provisions of impairment losses on related assets was RMB 1,714 million. The results announcement shows that in 2024, the performance decline of the Company was mainly influenced by the implementation of the National Volume Based Procurement (the “National VBP”), resulting in a year-on-year turnover (in the case that all medicines were directly sold by the Company) decrease of 28.8% to RMB2,691 million for three original drugs that were not selected.

    However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term pains, the development of exclusive and innovative drugs has many highlights and their potential has begun to emerge. In 2024, in the case that all medicines were directly sold by the Company, the turnover of exclusive and innovative products was RMB4,551 million, representing a year-on-year increase of 4.1%, accounting for 52.8% of the total turnover. This year, the Company has cumulatively had 5 innovative drugs enter into commercialization, but they were all in the early market introduction stage. In the future, as the marketed innovative drugs gradually expand into large-scale clinical applications and their sales ramp up rapidly, and as the quality innovative pipeline continues to be approved for marketing, the Company will enter a new cycle of quality and sustainable development driven by exclusive and innovative drugs.

    According to the announcement, in 2024, CMS submitted the NDAs for two novel drugs in China, including the innovative drug for the vitiligo treatment, ruxolitinib cream, established three innovative drug collaborations and three medical aesthetic product collaborations. As of the end of 2024, the Company has accumulated a total of nearly 40 short-term, medium-term, and long-term innovative pipeline products. In addition, the Company’s Southeast Asia business is poised for takeoff. This year, it has promoted more than five innovative drugs to submit market registration applications. The preparatory work for the Singapore factory of the associated company has been basically completed, and it is about to fully launch pharmaceutical CDMO and sales promotion businesses, cultivating a second growth curve.

    Product Competitiveness as the Core to Solidify the Innovation Growth Engine

    As a pharmaceutical commercialization leader with over three decades of experience in the pharmaceutical market and having promoted multiple marketed drugs to achieve leading market positions, CMS also maintains a keen market insight when deploying innovative drugs. It selects global FIC (First-in-Class) and BIC (Best-in-Class) innovative drugs based on front-line market demands, adhering to the “three-good-variety” screening criterias: having academic differentiated advantages, significant market potential and good competitive landscape, and high comprehensive return on investment.

    Looking at the Company’s marketed innovative drugs, the five products either have clear differentiation advantages compared to the existing products in the market or fill market gaps in particular areas. Therefore, they can provide valuable innovative treatment options for patients. For example, VELPHORO (Sucroferric Oxyhydroxide Chewable Tablets), used for phosphorus reduction in chronic kidney disease (CKD) patients, is the first iron-based, non-calcium phosphate binder (PB) approved by China’s NMPA, and filled the gap of phosphorus-lowering treatment for Chinese paediatric patients aged 12 to 18 years old with CKD stages 4-5 or CKD on dialysis. According to multiple global clinical studies and real-world research data (as published in academic journals including International Urology and Nephrology, and Clinical Nephrology) and the Chinese instruction of the product that compared with other PBs, patients maintained on VELPHORO used about 50% fewer PB pills/day, and a proportion of patients achieving target sP increased by 95%. ILUMETRI (Tildrakizumab Injection) is an innovative biological agent targeting to the p19 subunit of IL-23 for the treatment of moderate-to-severe plaque psoriasis. It only requires dosing once every three months during the maintenance period. With its excellent long-term efficacy, convenient dosing cycle, and good safety profile, the patient compliance is improved. With the excellent product strength as the core and leveraging the rich academic resources and promotional experience accumulated over the years, the Company is expected to rapidly enhance the market penetration and brand influence of its marketed products.

    The Company’s two innovative drugs, ruxolitinib cream and Desidustat Tablets, which are, currently in the NDA review stage in China and expected to be launched in 2025, are both considered to have good market potential. According to the announcement, ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European EMA for repigmentation in vitiligo as of now. If successfully approved for marketing, it will bring treatment hopes to more than ten million vitiligo patients in China who are suffering from the lack of effective drugs. Desidustat Tablets are used for treating anemia in non-dialysis adult, CKD patients and are administered orally. Its Chinese Phase III clinical trial shows that it performs well in efficacy, safety, and tolerability. Data shows that there are approximately 132 million CKD patients in China, and anemia is one of the frequent complications. After approved for marketing, the product is expected to further meet the anemia treatment needs of CKD patients.

    In addition, among the innovative pipeline products that the Company has reserved and are expected to be approved for marketing within the next 2 to 4 years, there are also several products with high market attention and industry-assessed potential to become FIC and BIC blockbuster drugs, such as Y-3 for stroke treatment, the highly selective small-molecule oral JAK1 inhibitor povorcitinib (for non-segmental vitiligo and hidradenitis suppurativa), the URAT1 inhibitor ABP-671 (for gout), the anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (for atopic dermatitis), the oral improved new drug ZUNVEYL (for Alzheimer’s disease), etc. These products will strongly support the Company’s continuous growth in future performance.

    Notably, CMS has always adhered to an efficient innovation strategy of “Collaborative R&D and In-house R&D” and attached great importance to maximizing the efficiency of R&D investment. From 2018 to 2024, the Company recorded cumulatively R&D expenditures of around RMB4,350 million, accounting for 7.6% of the turnover during the same period in the case that all medicines were directly sold by the Company, of which the R&D expenses were RMB880 million, accounting for 1.5% of the turnover during the same period in the case that all medicines were directly sold by the Company. Through relatively prudent R&D investment, the Company has successfully realized the project initiation, clinical development, and marketing of several quality innovative products, achieving extremely high innovation input-output efficiency. In addition, as of the end of 2024, the cash and bank deposit recorded RMB3,707 million, sufficiently safeguarding the continuous innovation and in-depth exploration of cutting-edge fields.

    Refining the Commercialization System Focused on Specialty to Empower the Release of Product Value

     

    The synergy between strong product power and efficient commercialization capabilities is the key to maintain the competitive advantage of the Company. CMS continuously upgrades its specialty-focused commercialization system, and forms an in-depth layout focusing on core specialties of cardio-cerebrovascular/gastroenterology, dermatology/medical aesthetics, and ophthalmology. Leveraging its accumulated extensive professional promotion networks and academic platforms, CMS will safeguard the successful commercialization of innovative products.

     

    Since its independent operation in 2021, “CMS Skinhealth”, is developing into a “leading, innovation-driven pharmaceutical company in China, specializing in skin health”. CMS Skinhealth has formed a comprehensive product portfolio centered on dermatology prescription drugs and extended to dermatology-grade skincare products and light medical aesthetic products. As of the end of 2024, the dermatology prescription portfolio of CMS Skinhealth has comprehensively covered dermatology diseases, such as vitiligo, psoriasis, atopic dermatitis, phlebitis, varicose veins, and hidradenitis suppurativa. As for dermatology-grade skincare products, the “Heling Soothing Product Series”, which are dedicated to sensitive skin care, have been further perfected. The Hirudoid® Azelaic Acid Skincare Series has been newly launched to provide a comprehensive acne-care solution. In the field of light medical aesthetic, the registration application of Poly-L-lactic Acid Microparticle Filler Injection in China has been accepted. Additionally, the Company has introduced three regenerative products, Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant, which are currently under the registrational clinical trial stages in China, further enhancing the light medical aesthetic product portfolio. CMS Skinhealth offers a diverse matrix of dermatological health and aesthetic products, providing comprehensive and integrated solutions to individuals with varying needs for skin health and beauty.

     

    Concurrently, “CMS Vision”, an independently operated ophthalmology business, focuses on the development and commercialization of ophthalmic prescription drugs, medical devices, and consumables. In China, a large number of patients suffer from ophthalmic diseases, and the burden of ophthalmic diseases is increasing significantly due to the population growth and aging. Leveraging on professional ophthalmic product portfolio, extensive network and channel resources, CMS Vision continuously strengthens its brand strength and academic position, aspiring to become a leading ophthalmic pharmaceutical and device company in China.

     

    As of the end of 2024, CMS had approximately 4,700 professional marketing and promotion related employees, with a promotion network covering over 50,000 hospitals and medical institutions, and approximately 300,000 retail pharmacies in China. Leveraging its efficient marketing and promotion team along with an extensive promotion network, the Company focuses on the marketed innovative drugs and core exclusive products, dynamically optimizes the marketing strategy, initiates real-world studies and post-marketing clinical trials, continuously accumulates academic evidence, strengthens the products academic influence, and accelerates the transformation into market value. Simultaneously, the Company has strengthened its expansion in the breadth and depth of coverage in the out-of-hospital market. Through integrated online and offline strategies and multi-channel collaboration, it has achieved a dual improvement in the out-of-hospital prescription traffic diversion and patient benefits.

     

    Starting with Southeast Asia and Cultivating the Second Growth Curve of Overseas Business

     

    While deeply developing in the Chinese market, CMS is also accelerating its pace of internationalization. Starting with Southeast Asia and leveraging the favorable opportunity of the rapidly growing local demand for high cost-effective pharmaceutical products, the Company is actively nurturing the growth engine of its overseas business, injecting new momentum into its long-term and sustainable development.

     

    In 2024, the Southeast Asia business, Rxilient Health, focusing on regional characteristics and disease spectrum features, executed a precise planning of its product portfolio and commercial pathways, and achieved notable milestones in the marketing registration for multiple products, laying the foundation for future market promotion and the realization of sales. Within this year, Rxilient Health has obtained the exclusive licenses in eleven Southeast Asian countries for povorcitinib, a selective small-molecule JAK1 Inhibitor, with the potential to provide a new treatment option for patients with autoimmune and inflammatory skin diseases. Meanwhile, Rxilient Health is actively advancing the registration of several innovative products in Southeast Asia, and/or in Hong Kong, Macau, and Taiwan, including ruxolitinib cream, ILUMETRI, LUMEBLUE, VALTOCO, VELPHORO and so on. Among them, ruxolitinib cream has been approved for marketing in Macau and Hong Kong for the treatment of vitiligo, and also submitted the registration applications in Singapore and Taiwan. Additionally, intravenous toripalimab (anti-PD-1 monoclonal antibody drug), collaborated by Rxilient Health and Junshi Biosciences, has submitted registration applications in Malaysia, the Philippines, Indonesia, Thailand, and Vietnam.

     

    Regarding the CDMO business, the associate company PharmaGend’s manufacturing plant in Tuas, Singapore has received the U.S. FDA GMP certification and successfully passed an on-site inspection by the Singapore HSA. It will provide CDMO services to global pharmaceutical companies and play a critical role in ensuring the safety of the Company’s overseas manufacturing supply chain.

     

    At the outset of a new journey, CMS proactively adapts to change and strides toward innovation, steadfastly executes the strategy of “innovation-driven, efficiency -priority, specialty breakthrough, and international expansion”. By reshaping the growth curve and cultivating a more diversified and resilient business framework, the Company is advancing into a new phase of quality development, providing patients with more quality therapeutic options while generating long-term stable returns for shareholders.

     

    CMS Disclaimer and Forward-Looking Statements

     

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

     

  • Ajit Sharma: A stock investment legend and a guiding light for Indian investors – Ajit Sharma’s books and investment wisdom

    In the ever-changing history of the global financial market, the stock investors who can really leave a strong mark are often those who have experienced the storms of the market but still stand firm. They not only look for opportunities in the waves of the market, but also shape their investment philosophy in the changes of the times. Ajit Sharma is such a legendary figure. Ajit Sharma is not only a senior trader in the stock investment and trading market, but also a mentor full of patriotism and charity.

    Personal profile: From an ordinary teenager to a trend-setter in the financial market

    Ajit Sharma was born in Mumbai, the financial center of India. This city is not only the home of the Indian Stock Exchange, but also the dream place of countless Indian investors. Since childhood, Ajit Sharma has been full of curiosity about the financial world. His father often took him to the hall of the stock exchange to let him feel the pulse of the market in the bustling crowd. However, what really made Ajit Sharma determined to become a stock investor was an unforgettable family accident. In 1991, the Indian economy was undergoing major reforms. The government relaxed market regulations and the capital market ushered in an unprecedented prosperity. However, opportunities and risks coexist. Ajit Sharma’s family suffered huge economic losses due to investment mistakes. This incident deeply touched the young Ajit Sharma and made him realize that investment is not just a game of buying and selling stocks, but a profound knowledge, a game of wisdom and patience.

    Ajit Sharma did not lose confidence in the market because of this, but was more eager to understand the rules. He began to read a lot of financial books, from Benjamin Graham’s “The Intelligent Investor” to George Soros’s “The Alchemy of Finance”, from classic cases in the Indian market to investment legends on Wall Street, he studied them carefully. During college, Ajit Sharma chose finance as his major and graduated with excellent grades. Ajit Sharma’s first job was as a stock analyst at a securities company in Mumbai, studying financial reports, tracking market trends, and writing analysis reports every day. However, he was not satisfied with being just a behind-the-scenes analyst. Ajit Sharma wanted to stand at the forefront of the market, really trade, and feel the storm of the market. Therefore, he made up his mind to go to Wall Street, the center of global finance, to start his real investment career.

    The cruel test of Wall Street: from a small role to a top trader

    When he came to New York, Ajit Sharma found that the competition on Wall Street was more cruel than he imagined. Here gathered the world’s top financial talents, and everyone was like a cheetah with a keen sense of smell, always looking for opportunities in the market. At first, Ajit Sharma was just an assistant trader in stock investment. His daily job was to sort out market data, analyze trends, and provide support to senior traders. But he was not discouraged by this. Instead, he took this opportunity to deeply learn the operating mechanism of the market. Ajit Sharma began to observe the decision-making patterns of senior traders, analyze the short-term fluctuations and long-term trends of the market, and summarize his own trading strategies.

    Ajit Sharma experienced the Asian financial crisis in 1997, the bursting of the Internet bubble in 2000, and the financial crisis in 2008 on Wall Street. Many investors suffered huge losses in the market turmoil, but Ajit Sharma successfully avoided risks with his keen market insight, and made decisive arrangements when the market was at a low point, and finally achieved remarkable returns. With his outstanding investment ability and sound risk control strategy, he gradually grew from an assistant trader to an independent trader, then to a senior trader, and finally became a top trader of a large investment bank on Wall Street.

    An investment guide book that condenses Ajit Sharma’s efforts

    As early as ten years ago, Ajit Sharma revealed in many interviews that he had always had a dream-to compile his many years of stock investment experience into a book to help Indian investors establish a truly scientific investment system. This is not only a market operation guide, but also a comprehensive book on investor mentality, market psychology, and risk control strategies. After several years of conception and arrangement, Ajit Sharma officially started writing in 2020. This book not only contains his investment experience, but also selects several classic market cases for analysis. Ajit Sharma hopes to let readers understand the operation mechanism of the market more intuitively through real cases. This book covers core content such as market cognition, investment psychology, trading strategies, risk management and wealth accumulation.

    The writing process of this book was full of challenges. Ajit Sharma spent countless nights organizing his investment notes, reviewing his investment experience over the past 20 years, and combining the characteristics of the Indian market to write a large number of case studies. After years of careful polishing, the book has finally entered the final publishing stage and is expected to be officially printed and released to the public in October 2025.

    Influence and educational mission: Building a learning platform for Indian investors

    In addition to publishing books, Ajit Sharma also founded the “Investor Academy”, which provides investment courses from basic to advanced, and regularly holds offline seminars and practical training camps. In addition, Ajit Sharma cooperates with many universities and financial institutions in India to promote the popularization of financial education, especially for young people and investors entering the market for the first time.

    The road to charity: using wealth to change more people’s lives

    Ajit Sharma always believes that the meaning of wealth is not only personal accumulation, but also how to use it to influence society. Therefore, he established the Future Light Foundation, which is committed to the following public welfare projects:

    Education support for poor children: Funding the construction of schools in remote areas of India and providing scholarships for children from poor families.

    Entrepreneurship support program: Providing funds and market guidance to young Indian entrepreneurs to help them realize their business dreams.

    Medical assistance and disaster relief: During the COVID-19 pandemic, Ajit Sharma launched the “Hands of Hope” charity action to provide financial support and donate medical supplies.

    Ajit Sharma’s future vision

    Ajit Sharma is not satisfied with his achievements. He plans to further expand the investment education platform and establish a dedicated investment research center to provide scientific market insights for Indian investors. Ajit Sharma believes that the Indian capital market is in its golden period of development, and the maturity of investors will directly determine the future of the market.

    “Investment is not just a game to make money, but also a test of wisdom, patience and risk management.” – Ajit Sharma

    Today, Ajit Sharma is not only an investor, but also a mentor, educator and philanthropist. Ajit Sharma’s books, investment courses, and philanthropy are influencing the future of investors across India, helping them achieve true financial freedom in the market.

    Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

  • Rolf Meieru – Chief Investment Officer (CIO)

    Rolf Meieru is a Chief Investment Officer (CIO) at Horizon Venture Fund, with over ten years of experience in the global financial markets. He specializes in high-frequency trading (HFT), statistical arbitrage (Stat Arb), market-neutral strategies, and volatility trading, employing sophisticated trading models and AI-driven strategies. His expertise in institutional investment management and ETF fund management has delivered outstanding performance.

    2020-2024: AI-Driven Complex Arbitrage Trading System

    Between 2020 and 2024, Rolf Meieru successfully integrated artificial intelligence (AI) with quantitative trading algorithms, developing an advanced institutional-grade arbitrage trading system that maintained stable returns even under extreme market conditions. The core elements of this system include:

    High-Frequency Trading (HFT) – Utilizing ultra-low-latency execution to optimize order placement and capture market microstructure arbitrage opportunities.

    Statistical Arbitrage (Stat Arb) – AI and machine learning-based models identifying historical correlations and mean-reversion patterns for profitable trading.

    Market-Neutral Strategy – Implementing hedging and market-neutral techniques to ensure consistent returns across different market environments.

    Volatility Trading – Utilizing VIX index and option strategies to construct high-yield portfolios during market turbulence.

    During the 2022-2023 period of significant global market volatility, Rolf Meieru trading team successfully leveraged AI-driven anomaly detection and automated trading strategies, outperforming major indices for four consecutive years and achieving a 42% compound annual return (CAGR) in the institutional hedge fund sector.

    Outstanding Performance of the Horizon Venture Fund

    Currently, the Horizon Venture Fund, led by Rolf Meieru, is achieving exceptional performance in the global markets. The fund’s superior returns are driven by:

    AI-Enhanced Trading Strategies – Leveraging AI for market trend forecasting, improving trading precision, and optimizing ETF asset allocation.

    Dynamic Cross-Asset Hedging – Diversified allocation across equities, fixed income, forex, and commodities, generating low-correlation returns.

    Quantitative Trading & Active Management – Adjusting ETF weightings actively, capturing upside gains while maintaining stability during downturns.

    Deep Market Exploration – Utilizing big data analysis to identify high-growth markets and sectors, securing consistent alpha returns.

    Volatility Arbitrage & Event-Driven Strategies – Adapting to market events, central bank policies, and geopolitical shifts to optimize trading strategies.

    In H1 2024, Rolf Meieru ETF trading team achieved over 30% returns, making Horizon Venture Fund a standout performer among global institutional investors.

    Future Strategic Directions

    In 2025, Rolf Meieru plans to further innovate AI-driven quantitative trading models, reinforcing Horizo​​n Venture Fund expansion into global markets, blockchain finance, emerging market ETFs, and macro hedge funds. Additionally, he will focus on optimizing algorithmic trading strategies, deep liquidity management, and structured derivatives investments, ensuring that Horizon Venture Fund remains a leading institutional-grade trading fund.

    “The market is constantly evolving. We must remain at the forefront, leveraging technology and data to build a dynamic investment system that adapts to market shifts.” — Rolf Meieru

    As a Client Portfolio Specialist at Horizo​​n Venture Fund, Rolf Meieru demonstrates exceptional expertise in high-frequency trading, quantitative arbitrage, market-neutral strategies, and volatility trading. His success in integrating AI with complex arbitrage trading systems has resulted in exceptional returns, positioning Horizon Venture Fund as a top-tier investment product in the global market.

    His investment philosophy and cutting-edge trading methodologies continue to drive market innovation, setting new benchmarks in financial technology and institutional trading strategies.

    Media Contact:

    Official website: https://www.horizon.mn

    Email: investments@horizoncapital.info

    Contact person: Rolf Meieru

    Address: Harbor Financial Tower 350 Madison Avenue, 24th Floor New York, NY 10017 USA

    Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

  • Vantara: A Nature-First Approach to Wildlife Rescue and Rehabilitation

    Mumbai, India: In a world where urbanisation and industrialisation often come at the cost of nature, Vantara, an animal rehabilitation and conservation centre by the Reliance Group, stands as a beacon of hope for wildlife. Nestled in the serene expanse of Jamnagar, Gujarat, this pioneering initiative is dedicated to animal welfare, conservation, and ecological restoration.

    The name Vantara derives from Sanskrit, where ‘Van’ means forest and ‘Tara’ means protector or saviour, translating to “Protector of the Forest.” True to its name, Vantara offers a second chance at life to rescued and rehabilitated animals. Spanning over 3,000 acres, it provides a safe and nurturing environment for over 2,000 animals across 43 species, including big cats, elephants, birds, and reptiles, many of whom have been rescued from captivity, circuses, illegal trafficking, or distressing conditions.

    Vantara prioritizes rehabilitation, ensuring that animals live in enclosures designed to mimic their natural habitats. The facility boasts world-class veterinary care, species-specific diets, and a team of 2,100 dedicated caregivers and conservationists who oversee the animals’ nutrition, medical treatment, and overall well-being.

    The centre is particularly notable for its 600-acre elephant habitat, which includes a specialized hospital featuring advanced treatments such as hyperbaric oxygen therapy, laser care, and a jacuzzi for arthritis relief. Additionally, a state-of-the-art medical research centre, spanning 1 lakh sq. ft., is equipped with MRI, X-ray, ICU, and CT scan facilities, ensuring comprehensive healthcare for rescued animals. Scientifically planned enclosures, including hydrotherapy pools and water bodies, aid in rehabilitation, while global partnerships with wildlife experts enhance conservation research and academic collaborations.

    Vantara has played a crucial role in several conservation success stories, including the reintroduction of the Spix’s macaw (Cyanopsitta spixii), which was declared extinct in the wild in the 2000s. Recently, the species was transferred from the Association for the Conservation of Threatened Parrots (ACTP) breeding centre in Germany to Brazil, with Vantara as a key partner in the global reintroduction programme, providing vital resources and expert guidance. Additionally, Vantara has been instrumental in rescuing elephants from Arunachal Pradesh, now thriving in a chain-free habitat. The initiative has also supported the development of vaccines for elephants through its resources.

    Vantara is the brainchild of Anant Ambani, son of Mukesh Ambani, one of India’s most celebrated billionaires. Anant Ambani was recently honoured with the prestigious ‘Prani Mitra’ award by the Animal Welfare Board of India, the country’s highest recognition for contributions to animal welfare.

    Beyond conservation, Vantara aligns with Reliance’s broader vision of sustainability, reinforcing its goal of becoming a net-zero company by 2035. Through habitat restoration, cutting-edge animal care, and a commitment to ecological balance, Vantara stands as a testament to what can be achieved when compassion meets action.

  • NJHealth NMN Ambassador Li Nan Xing Advocates Healthy Ageing

    SINGAPORE – Singaporean actor and cultural icon Li Nan Xing becomes the spokesperson of NJHealth NMN 20000mg. Known for his enduring vitality and charisma, Li Nan Xing’s endorsement underscores the product’s efficacy and aligns with his personal commitment to maintaining vitality as he ages.

    Li Nan Xing, often called the “King of Caldecott Hill,” is no stranger to the demands of a high-pressure lifestyle. At 60, he remains a beacon of health and resilience, and he credits NJHealth NMN 20000mg for helping him sustain his energy and well-being.

    “As someone who believes in ageing gracefully while staying active, I was drawn to NJHealth NMN 20000mg for its science-backed benefits,” Li Nan Xing said.

    “Since incorporating it into my daily routine, I’ve noticed a significant boost in my energy and focus. It’s a game-changer for anyone looking to maintain their vitality and zest for life.”

    Empowering Singaporeans to Age Smarter – Unlocking the Science of Healthy Ageing

    NJHealth NMN 20000mg is specially formulated with patented technology to boost NAD⁺ levels to support healthy ageing. Each capsule contains 200mg of NMN with a recommended dose of two capsules daily, or as recommended by healthcare professionals. Manufactured in Japan under Good Manufacturing Practices (GMP), the supplement is rigorously tested by third-party accredited labs for purity and quality.

    Nicotinamide Mononucleotide (NMN)is a derivative of Vitamin B3 and a precursor of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for energy and cell function. NAD+ also supports sirtuins, which regulate metabolism and gene health. Since NAD+ declines with age, boosting its levels through NMN supports healthy cell function, increase energy levels, and promotes overall well-being.

    NJHealth NMN 20000mg is now available online and at Guardian pharmacy outlets in Singapore. Visit www.njhealth.com.sg for product details and testimonials.

    About NJHealth

    NJHealth is a new brand under Nin Jiom Group. NJHealth NMN 20000mg healthy ageing supplement is the first product under the new NJHealth brand name. Nin Jiom is an iconic name widely known in Asia. Founded in 1946, the pioneer in modern Chinese medicine is best known for Nin Jiom Pei Pa Koa, a herbal cough syrup trusted for generations for its ability to nourish the lung, eliminate phlegm, relieve cough, soothe the throat and remove heat. The NJHealth brand has been created to showcase another side of the company, one that is more from a scientific and technological perspective.  Singapore is the first market for its NMN 20000mg healthy ageing supplement which comes in 100-capsule bottles.

    For product enquiries, please contact Luen Wah Medical Co (S) Pte Ltd at +65 6533 9144.

    For other media enquiries, please contact Mr. Marcus Chang at +65 9479 5657.

     

    Media Contact

    Company: NJHealth

    Contact: Media Team

    Website: https://www.njhealth.com.sg/

    SOURCE: NJHealth

  • ZSN3 Series High Power Power Supply Products

    High power supply: ZSN3 series from Zhejiang Leyu Electric Co., Ltd. – ideal for industry and scientific research

    In modern industry and scientific research, high power supply is an indispensable core equipment. It provides stable and reliable power support for various high-energy consumption systems and precision instruments, ensuring production efficiency and experimental accuracy. As a leading company in the field of power supply solutions, the ZSN3 series of high power supply launched by Zhejiang Leyu Electric Co., Ltd. has become a star product in the market with its excellent technical performance and diverse application scenarios. This article will discuss in detail the definition, technical specifications, application scenarios and purchase recommendations of high power supply to help users better understand and choose the power supply equipment that suits them.

    Definition of high-power power supply

    High-power power supply refers to power supply equipment with output power usually ranging from several kilowatts (kW) to tens of kilowatts or even higher. Unlike ordinary household power supplies, high-power power supplies are designed for large equipment and complex systems, and can provide high voltage, high current, and maintain extremely high stability. They play a key role in industrial automation, scientific research experiments, and new energy. Zhejiang Leyu Electric Co., Ltd.’s ZSN3 series is a representative product in this field, and its design fully meets the dual needs of high output power and stability.

    Technical Specifications

    The ZSN3 series high-power power supply adopts advanced power electronics technology and has the following core technical specifications:

    * Output power: ranging from 10kW to 100kW, which can be flexibly selected according to user needs.

    * Voltage range: 0-1000V, the output voltage is adjustable, suitable for a variety of devices.

    * Current range: 0-100A, the current output is also adjustable, providing greater flexibility.

    * Efficiency: up to 95%, energy saving and environmental protection, reducing long-term operating costs.

    * Stability: voltage fluctuation is less than 0.1%, and current fluctuation is less than 0.5%, ensuring accurate and reliable power output.

    * Protection function: built-in overvoltage, overcurrent, overheating and other multiple protection mechanisms to ensure the safety of equipment and users.

    The following is the technical parameter table of the ZSN3 series:

    ZSN3-5K0 series

    IMG_256
     

    These technical features make the ZSN3 series stand out in the high-power power supply market and become the first choice for industrial and scientific research users.

    Application scenarios

    The ZSN3 series high-power power supply is widely used in the following fields due to its superior performance:

    Industrial automation

    In industrial production, large-scale mechanical equipment and automated production lines require stable power support. The ZSN3 series can provide high-output power for motors, robots and processing equipment to ensure efficient and smooth production processes. For example, in the field of automobile manufacturing, the ZSN3 series is used to drive heavy equipment on assembly lines.

    Scientific research experiments

    In scientific research fields such as physics, chemistry and materials science, many experimental equipment (such as particle accelerators and lasers) have extremely high requirements for the voltage and current accuracy of the power supply. The high stability and adjustability of the ZSN3 series make it an ideal choice in the laboratory.

    New energy systems

    In the field of new energy such as solar and wind energy, high-power power supplies are often used as core components of inverters or chargers. The ZSN3 series can efficiently convert and distribute electricity to support the development and application of renewable energy.

    Purchase suggestions

    Choosing a suitable high-power power supply requires comprehensive consideration of multiple factors. Here are some practical suggestions:

    * Power requirements: First, clarify the power requirements of the device and choose a model with matching output power. For example, a 10kW model can be selected for small and medium-sized equipment, while a large system may require 50kW or more.

    * Voltage and current range: Make sure the output range of the power supply covers the working requirements of the equipment to avoid performance problems caused by parameter mismatch.

    * Stability: A high-stability power supply can reduce the failure rate of equipment and extend its service life. The low fluctuation characteristics of the ZSN3 series are an important advantage.

    * Protection function: The perfect overload protection function can effectively prevent accidental damage, especially in scenarios with long-term operation.

    * Brand reputation: Choosing a brand with a good reputation like Zhejiang Leyu Electric Co., Ltd. can not only guarantee product quality, but also enjoy reliable after-sales service.

    Customer reviews and success stories

    To enhance user trust, here is a review of the ZSN3 series by an actual user:

    “We use the ZSN3 series high-power power supply on our automated production line, and it has never failed in more than a year. Its stability has greatly improved our production efficiency, and it is really trustworthy!”

    —An engineer at an automobile manufacturing plant

    IMG_256

    In addition, in a well-known scientific research institution, the ZSN3 series is used to support high-energy physics experiments. Researchers said that its precise voltage control and efficient heat dissipation design significantly improved the reliability of experimental data.

    Installation and Usage Support

    To help users get started quickly, Zhejiang Leyu Electric Co., Ltd. provides a detailed installation video tutorial for the ZSN3 series. The video covers the complete process from unpacking inspection to wiring installation, ensuring that users can complete equipment deployment safely and efficiently.

    Conclusion

    Whether in industrial automation, scientific research experiments or new energy fields, Zhejiang Leyu Electric Co., Ltd.’s ZSN3 series high-power power supplies have demonstrated unparalleled performance and reliability. Its high output power, high stability and diverse application scenarios make it an ideal choice for users when choosing a high power power supply. Through reasonable purchase and use, the ZSN3 series can not only meet current power needs, but also provide solid support for future technology upgrades.

    Media contact

    Company Name : LEYU

    Contact Person: Marketing Team

    Email: sales@leyuelec.com

    Tele: +86-577-6299-8958

    Website: http://leyuelec.com/

  • The Ultimate Weapon of Smart Money: How AlphaHive Helps Ordinary Investors Grasp the Market Opportunities

    In the crypto market, information asymmetry has always been the biggest pain point for ordinary investors. The high volatility of the market, lack of transparency, and the increasing number of asset types make it difficult for investors to accurately judge market trends and obtain stable Alpha (excess returns). At the same time, Smart Money – professional investment institutions or individual investors with a deep investment research background, information advantages and strong capital strength, can cross the bull and bear markets, accurately capture market opportunities, and achieve returns far exceeding those of ordinary investors.

    But are ordinary investors destined to be passive followers of the market? AlphaHive empowers ordinary investors with the ability to master smart money strategies through smart trading tools, on-chain data analysis and social mining, making decentralized finance truly democratized. Whether you are a senior trader or an investor who has just entered the Web3 world, you can enjoy institutional-level market insights and investment decision support through AlphaHive, truly become an Alpha hunter, and reap the market’s excess returns.

    Core characteristics of smart money

    In traditional financial markets, institutional investors have always dominated the market with data analysis, internal information and quantitative trading strategies. Smart money is a collection of these professional investors, and they often have the following characteristics:

    First, information advantage. Smart money can obtain market data, industry trends, policy trends and other information that ordinary investors cannot easily obtain.

    Second, capital advantage. Smart money has a large capital scale, which can support it to carry out more complex trading strategies, such as quantitative trading, high-frequency trading, arbitrage strategies, etc.

    Third, strategic advantage. Smart money’s investment decisions are based on a mature investment research system, and its trading strategies are far more reliable than the subjective judgment of ordinary investors after historical data backtesting and market testing.

    However, this information and strategies are often monopolized by smart money, and ordinary investors are difficult to obtain directly, resulting in serious information asymmetry in the market and a profit gap between smart money and retail investors. AlphaHive bridges this gap through technical means, allowing ordinary investors to obtain corresponding market advantages.

     

    How AlphaHive helps ordinary investors track smart money

    AlphaHive helps ordinary investors obtain trading signals from smart money and convert this information into actual investment returns through core functions such as on-chain data analysis, smart trading tools and social mining.

    AlphaHive HiveSignal provides on-chain data analysis services, tracks the flow of smart money funds in real time, and provides valuable market insights. By intelligently monitoring whale wallets, users can track the flow of funds from well-known institutions and large wallet addresses. HiveSignal can also push signals in time when smart money buys or sells a certain asset on a large scale, helping users to respond quickly. In addition, the system can also combine social data to analyze market hotspots and assist investment decisions.

    SwarmTrade is AlphaHive’s core trading tool, which supports users to automatically execute smart money’s trading strategies and reduce the complexity of transaction execution. Users can use SwarmTrade to copy the strategies of top traders with one click, and smart contracts automatically synchronize transactions without manual operation. The system also supports smart arbitrage functions, which use price differences in the DeFi ecosystem for arbitrage and improve transaction efficiency. In addition, SwarmTrade also provides strategy pool management, where users can choose trading strategies with different risk preferences and manage their own investment portfolios in a personalized way.

    AlphaHive encourages users to share market information and investment insights through a social mining mechanism to build a “swarm intelligence” ecosystem. Users can get $Pollen token rewards by publishing market analysis, liking interactions, and sharing Alpha signals. This not only enhances information sharing among users, but also promotes the circulation of knowledge throughout the AlphaHive community and improves collective investment capabilities.

     

    AlphaHive’s unique competitive advantage

    In the fields of DeFi and SocialFi, although there are some well-known projects that provide trading tools or social functions, AlphaHive has an incomparable competitive advantage:

    AlphaHive combines on-chain data analysis, smart trading, and social mining to build a closed-loop ecosystem. Compared with other DeFi platforms that only provide trading tools, AlphaHive provides market intelligence analysis through HiveSignal, SwarmTrade is responsible for strategy execution, Social Mining promotes community interaction, and DAO governance ensures long-term fairness, forming a complete decentralized financial system.

    , AlphaHive has a powerful NFT economy and user identity system, and KOLs and community contributors can obtain exclusive rights through NFT. Users can obtain market analysis and private trading strategies through limited NFTs, thereby enhancing their market influence and personal brand value.

    Adopting the DAO governance model, AlphaHive truly realizes the democratization of decentralized finance. Users holding $HIVE tokens can vote to decide the future development direction of the platform to ensure the fairness and transparency of the ecology. Through DAO governance, AlphaHive users are not only users of the platform, but also co-decision makers for its long-term development.

    Finally

    Through intelligent trading tools, on-chain data analysis and social mining, AlphaHive enables ordinary investors to enjoy institutional-level market insights and investment decision support, and truly become Alpha hunters. The platform not only provides efficient trading tools, but also builds a complete ecosystem that enables users to share market information, optimize investment strategies, and earn income through social interactions.

    As decentralized finance continues to develop, the influence of smart money will continue to expand, and AlphaHive, as a bridge connecting ordinary investors with smart money, will play a vital role in the future DeFi ecosystem. Through AlphaHive, ordinary investors can not only narrow the income gap with smart money, but also occupy a favorable position in the new world of decentralized finance and control their own financial future.

    Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

  • CrushOn AI: Ultimate NSFW Anime AI Chat Revolution in 2025

    In 2025, anime AI chat platforms have taken the online entertainment world by storm. Among these cutting-edge services, CrushOn.AI has emerged as the go-to destination for anime fans craving authentic conversations with their favorite character types.

    Breaking New Ground for Anime Fans

    The anime community has fallen head over heels for CrushOn.AI’s character-driven platform. Unlike traditional media, this interactive playground lets fans directly engage with personalities inspired by beloved anime archetypes. From fiery tsunderes to mysterious mentors, the platform captures everything that makes anime characters so damn addictive.

    Why CrushOn’s Anime AI Chat Crushes the Competition

    – Lifelike Character Design: Each AI persona comes with rich backstories, distinct speech patterns, and visuals that stay true to anime traditions

    – Lightning-Fast Responses: The platform’s neural network fires back replies instantly, keeping conversations flowing naturally

    – Vast Anime Universe: Dive into everything from slice-of-life scenarios to epic fantasy quests

    – Gets Your Anime References: Smart algorithms actually understand anime-specific jokes, tropes, and cultural nuances

    – Shaped by Real Fans: User feedback constantly refines characters and conversations

    The Tech Wizardry Behind the Scenes

    CrushOn‘s nsfw AI chat runs on bleeding-edge tech specifically built for character-based interactions. Their proprietary “Persona Engine” keeps character traits consistent while conversations evolve naturally. Meanwhile, the “Anime Context Framework” ensures responses feel authentically anime in both content and style.

    Built by Otaku, for Otaku

    The interface pulls inspiration from visual novels and anime aesthetics, creating an immersive world that feels like home to fans. Users can:

    – Pick from various settings (high school, fantasy realm, modern city)

    – Set character moods and scenarios

    – Build relationships that deepen over time

    – Save their favorite moments in a personal collection

    What’s Next for Anime AI Interaction

    As CrushOn continues pushing boundaries, upcoming features include shared storytelling where multiple users can interact within the same narrative universe. Voice integration with Japanese and English options will make these digital companions feel even more real.

    For anime fans longing for connections with characters who truly get them, CrushOn’s platform delivers an unmatched opportunity to bring the emotional depth of anime relationships into interactive digital space, turning what once lived only in imagination into an ongoing experience.

  • UPCX Announces Global Staking Program to Promote Democratization of Blockchain Finance

    The blockchain payment platform UPCX has announced the launch of an exciting staking event, offering participants the chance to share a prize pool worth $20,000 (approximately 7,500 UPC). This event is exclusively designed for UPCX Stakers and will run from March 12, 2025, to April 12, 2025.

    Event Rules:

    – Lucrative Rewards: In addition to the APY provided by the UPCX platform—20% (30 days), 50% (90 days), and 100% (180 days)—participants can earn an additional bonus of up to 30%.

    – Flexible Staking Options: Users can choose from 30-day, 90-day, or 180-day locking periods, sharing different prize pools based on their staked amount and duration.

    – Prize Pool Distribution:

    Stake over 10 UPC: Share a 1,000 UPC prize pool

    Stake over 500 UPC: Share a 2,500 UPC prize pool

    Stake over 1,000 UPC: Share a 3,000 UPC prize pool

    Additional Long-Term Rewards: Stake 25 UPC for 90 days to share a 300 UPC pool, or stake 25 UPC for 180 days to share a 600 UPC pool

    – How to Participate:

    Visit the UPCX Staking Platform to stake any amount of $UPC: https://upcx-staking.io/

    Fill out the event form to claim rewards, which are distributed proportionally to your staked amount: https://t.co/bIXuOGAoPs

    UPCX emphasizes that this event aims to promote the democratization of blockchain finance, enabling global users to benefit from the advantages of blockchain technology. During the event, participants not only have the opportunity to earn substantial rewards but also experience the secure, transparent, and efficient financial services offered by the UPCX platform. UPCX is committed to reaching global markets, strictly adhering to legal and regulatory requirements in each region to ensure service compliance. Currently, $UPC is listed on several well-known trading platforms, including MEXC, Bitget, Gate.io, WEEX, and Websea, providing convenient trading channels for users worldwide.

    More about UPCX:

    UPCX is a blockchain-based open-source payment platform that aims to provide secure, transparent, and compliant financial services to global users. It supports fast payments, smart contracts, cross-asset transactions, user-issued assets (UIA), non-fungible tokens (NFA), and stablecoins. Moreover, it offers a decentralized exchange (DEX), APIs, and SDKs, allows customized payment solutions, and integrates POS applications and hardware wallets for enhanced security, building a one-stop financial ecosystem.

    Official website: https://upcx.io/

    X: https://x.com/Upcxofficial

    X(upcxcmo): https://x.com/kokisato_upcx

    Telegram: https://t.me/UPCXofficial

    Discord: https://discord.gg/YmtgK7NURF